fda announcement semaglutide 📢 has determined the shortage of injection products, a glucagon-like peptide 1 (GLP-1) medication, is resolved. Patients and prescribers may still see intermittent and limited localized supply disruptions as the FDA declares end to Wegovy

A grass carp model with an antibiotic-disrupted intestinal microbiota

Excess skin may show up around the belly area or even the face and can sometimes cause its own issues: This excess skin may feel uncomfortable, make clothes fit awkwardly, lead to irritation and even hygiene challenges

one 68-week, randomized, double-blind trial that investigated two different doses of WEGOVY injection versus placebo and two 72-week randomized, double-blind trials that investigated two different doses of WEGOVY injection versus placebo

Nature Medicine, 2024 How much lower blood sugar (HbA1c, a three-month marker) ran in the higher-dose groups of the Phase 2 diabetes trial

Maresin1 ameliorates MSU crystal-induced inflammation by upregulating Prdx5 expression